Tim van Hauwermeiren
Fondatore presso ARGENX SE
Patrimonio netto: 34 M $ in data 30/04/2024
Profilo
Fondatore di argenx SE, Tim van Hauwermeiren occupa attualmente la posizione di presidente di Aelin Therapeutics NV e di amministratore delegato e direttore esecutivo di argenx SE. È anche nel consiglio di amministrazione di iTeos Therapeutics SA e iTeos Therapeutics, Inc. In passato ha ricoperto la posizione di Group Head presso Procter & Gamble Co. e Senior Manager-Business Development presso Ablynx NV. Ha ricevuto un MBA dalla Vlerick Leuven Gent Management School e una laurea e un diploma di laurea presso l'Università di Ghent.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
ARGEN-X SE
0.12% | 20/02/2024 | 71 986 ( 0.12% ) | 27 M $ | 30/04/2024 |
ARGENX SE ADR
0.03% | 31/08/2023 | 18 100 ( 0.03% ) | 7 M $ | 30/04/2024 |
ITEOS THERAPEUTICS, INC.
-.--% | 16/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Posizioni attive di Tim van Hauwermeiren
Società | Posizione | Inizio |
---|---|---|
ARGENX SE | Fondatore | 01/01/2008 |
ITEOS THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/06/2018 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Direttore/Membro del Consiglio | 27/06/2018 |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Presidente | - |
Precedenti posizioni note di Tim van Hauwermeiren
Società | Posizione | Fine |
---|---|---|
RAYZEBIO, INC. | Direttore/Membro del Consiglio | 26/02/2024 |
ABLYNX | Corporate Officer/Principal | - |
PROCTER & GAMBLE COMPANY | Corporate Officer/Principal | - |
Formazione di Tim van Hauwermeiren
Vlerick Leuven Gent Management School | Masters Business Admin |
Ghent University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
ARGENX SE | Health Technology |
PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
ITEOS THERAPEUTICS, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
Aziende private | 3 |
---|---|
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Health Technology |
- Borsa valori
- Insiders
- Tim van Hauwermeiren